1982年毕业于兰州大学化学系；
1982年8月至1988年8月在美国耶鲁大学学习有机合成化学，获得博士学位；
1988年8月至2010年10月任职于默克制药公司加拿大研发中心，从事新药研发；
2010年11月创立了加拿大贝达药业，从事抗肿瘤小分子新药研发；
2012年4月获得南京市“321”人才计划支持，创立南京奥昭生物科技有限公司， 重点推进抗肿瘤靶向先导化合物的临床前研究工作；
2013年10月加入中国科学院上海有机所生物与化学交叉研究中心。
(1) Wang, Z., Deschenes, D. "Enantiospecific synthesis via sequential diastereofacial and diastereotopic group selective reactions: enantiodivergent synthesis of syn-1,3-polyols." J. Am. Chem. Soc, 1992, 114, 1090-1091.
(2) Wang, Z., Warder, S., Perrier, H., Grimm, E. "A straightforward approach to the synthesis of the tricyclic core of taxanes." J. Org. Chem. 1993, 58, 2931-2932
(3) Prasit, P., Wang, Z., Brideau, C., Chan, C.-C., Charleson, S., Cromlish, W., Ethier, D., . Evans, J. F., Ford-Hutchinson, A. W., Gauthier, J. Y., Gordon, R., Guay, J., Gresser, M., S. Kargman, S., Kennedy, B., Leblanc, Y., Léger, S. , Mancini, J., O'Neill, G. P., Ouellet, M, Percival, D., Perrier, H., Riendeau, D., Rodger, I. W., Tagari, P. Thérien, M., Vickers, P., Wong, E., Xu, L.-J., Young, R. N. and Zamboni, R. "Rofecoxib, [MK 966, Vioxx？, 4-( 4'-Methylsulfonylphenyl)-3- -2 Phenyl (5H)-Furanone]: the Discovery of a Selective and Orally Active Cyclooxygenase-2 Inhibitor." Bioorg. Med. Chem. Lett. 9, 1999,: 1773-78.
(4) Baskin,J.M. and Wang,Z. “A mild, convenient synthesis of sulfinates and sulfonamides from alkyl and aryl halides”. Tetrahedron Lett. 43 2002: 8479-8483.
(5) Baskin,J.M. and Wang,Z. “An Efficient Copper Catalyst for the Formation of Sulfones from Sulfinic Acid Salts and Aryl Iodides.” Organic Letters 4, 2002: 4423-4425.
(6) Beaulieu, C., Wang, Z., Denis, D., Greig, G.M., Lamontagne, S., Slipetz, D., O'Neill, G.P., and Wang, J. “Benzimidazoles as New Potent and Selective DP Antagonists for the treatment of Allergic Rhinitis”. Bioorg. Med. Chem. Lett. 14, 2004: 3195-3199.
(7) Beaulieu, C., Wang, Z., Guay, D., and Evans, D.A. “A mild and efficient new synthesis of aryl sulfones from boronic acids and sulfinic acid salts”. Tetrahedron Lett. 45, 2004: 3233-3236.
(8) Sturino,C.F., Lachance,N., Boyd,M.J., Berthelette,C., Li,L., Roy,B., Scheigetz,J., Tsou,N.N., Bateman,K.P., Day,S.H., Levesque,J.-F., Carrière,M.-C., Denis,D., Greig,G.M., Kargman,S.L., Lamontagne,S., Mathieu,M.-C., Sawyer,N., Slipetz,D., Jones,T.R., Nicoll-Griffith,D.A., Wang,Z., O'Neill,G.P., Zamboni,R.J., Metters,K.M., and Young,R.N. (2006). “Discovery of mk-0524, a potent and selective pgd2 receptor antagonist.” Journal of Medicinal Chemistry, 50, 2007, 794-806.
(9) Colucci, J.; Boyd, M.; Berthelette, C.; Chiasson, J.-F.; Wang, Z.; Ducharme, Y.; Friesen, R.; Wrona, M.; Levesque, J.-F.; Denis, D.; Mathieu, M.-C.; Stocco, R.; Therien, A. G..; Clarke, P.; Rowland, S.; Xu, D.; Han, Y. “Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl)amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory painl.” Bioorganic & Medicinal Chemistry Letters (2010), 20(12), 3760-3763.
(10) Li, L.; Berthelette, C.; Chateauneuf, A.; Ouellet, M.; Sturino, C. F.; Wang, Z., “Potent and selective 5-LO inhibitor bearing benzothiophene pharmacophore: Discovery of MK-5286”, Bioorganic & Medicinal Chemistry Letters (2010), 20(24), 7440-7443.
(11) Gallant, M.; Beaulieu, C.; Berthelette, C.; Colucci, J.; Crackower, M. A..; Dalton, C.; Denis, D.; Ducharme, Y.; Friesen, R. W..; Guay, D.; Gervais, F. G.; Hamel, M.; Houle, R.; Krawczyk, C. M.; Kosjek, B.; Lau, S.; Leblanc, Y.; Lee, E. E.; Levesque, J.-F.; Mellon, C.; Molinaro, C.; Mullet, W.; O'Neill, G. P.; O'Shea, P.; Sawyer, N.; Sillaots, S.; Simard, D.; Slipetz, D.; Stocco, R.; Sorensen, D.; Truong, V. L.; Wong, E.; Wu, J.; Zaghdane, H.; Wang, Z., “Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases”, Bioorganic & Medicinal Chemistry Letters (2011), 21(1), 288-293.
